Failure of alemtuzumab therapy to control MOG encephalomyelitis

Neurology. 2017 Jul 11;89(2):207-209. doi: 10.1212/WNL.0000000000004087. Epub 2017 Jun 9.

Authors

Brigitte Wildemann¹, Sven Jarius², Alexander Schwarz², Ricarda Diem², Andrea Viehöver², Stefan Hähnel², Markus Reindl², Mirjam Korporal-Kuhnke²

Affiliations

¹ From University Hospital Heidelberg (B.W., S.J., A.S., R.D., A.V., S.H., M.K.-K.), Germany; and Medical University Innsbruck (M.R.), Austria. [email protected].
² From University Hospital Heidelberg (B.W., S.J., A.S., R.D., A.V., S.H., M.K.-K.), Germany; and Medical University Innsbruck (M.R.), Austria.

PMID: 28600462
DOI: 10.1212/WNL.0000000000004087

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Alemtuzumab / therapeutic use*
Diagnostic Errors*
Encephalomyelitis / complications
Encephalomyelitis / drug therapy*
Encephalomyelitis / immunology
Female
Humans
Immunosuppressive Agents / therapeutic use
Multiple Sclerosis / complications
Multiple Sclerosis / diagnosis*
Multiple Sclerosis / drug therapy*
Myelin-Oligodendrocyte Glycoprotein / immunology*
Treatment Failure

Substances

Immunosuppressive Agents
Myelin-Oligodendrocyte Glycoprotein
Alemtuzumab